Treatment of patients with Waldenstrom macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group
- Author(s)
- Talaulikar, D; Joshua, D; Ho, PJ; Gibson, J; Quach, H; Gibbs, S; Ling, S; Ward, C; Augustson, BM; Trotman, J; Harrison, SJ; Tam, CS; Medical and Scientific Advisory Group, Myeloma Australia;
- Details
- Publication Year 2023-04,Volume 53,Issue #4,Page 599-609
- Journal Title
- Internal Medicine Journal
- Publication Type
- Guideline
- Abstract
- Waldenstrom macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of IgM paraprotein, bone marrow infiltration by clonal small B lymphocytes with plasmacytic differentiation and the MYD88 L265P mutation in >90% of cases. Traditionally, WM has been treated with chemoimmunotherapy. Recent trials have demonstrated the efficacy and safety of Bruton tyrosine kinase inhibitors in WM, both as monotherapy and in combination with other drugs. There is emerging evidence on the use of other agents including B-cell lymphoma 2 inhibitors and on the treatment of rare presentations of WM. In this update, the Medical and Scientific Advisory Group of Myeloma Australia reviews the available evidence on the treatment of WM since the last publication in 2017 and provides specific recommendations to assist Australian clinicians in the management of this disease.
- Publisher
- Wiley
- Keywords
- Humans; *Waldenstrom Macroglobulinemia/diagnosis/drug therapy/genetics; *Multiple Myeloma/drug therapy; Australia/epidemiology; *Antineoplastic Agents/therapeutic use; Bone Marrow/pathology; Mutation; Myeloid Differentiation Factor 88/genetics; Bruton tyrosine kinase inhibitor; Waldenstrom macroglobulinaemia; treatment
- Department(s)
- Clinical Haematology
- PubMed ID
- 36441109
- Publisher's Version
- https://doi.org/10.1111/imj.15980
- Open Access at Publisher's Site
https://doi.org/10.1111/imj.15980- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-08-07 07:16:19
Last Modified: 2023-08-07 07:17:40